Ignite Creation Date:
2025-12-24 @ 11:44 PM
Ignite Modification Date:
2026-03-04 @ 8:23 PM
Study NCT ID:
NCT00863551
Status:
COMPLETED
Last Update Posted:
2016-02-26
First Post:
2009-03-16
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Sanctura Muscarinic Receptor Antagonist Resists Transport (SMART) Trial
Sponsor:
Allergan
Organization:
Study Overview
Official Title:
None
Status:
COMPLETED
Status Verified Date:
2016-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study evaluates the penetration through the blood-brain-barrier of trospium chloride at plasma steady state (Day 10) in elderly subjects with overactive bladder symptoms. Trospium levels in cerebrospinal fluid (CSF) and peak and trough plasma levels will be measured. Baseline and day 10 post-dose neurocognitive testing will be compared using a reliable change index to assess if any study subject shows evidence of a clinically and statistically significant change in memory.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?:
Secondary ID Infos
| Secondary ID | Type | Domain | Link | View |
|---|---|---|---|---|
| SMART Trial | OTHER | Allergan | View |